This interactive discussion explores the complexities of managing hepatitis B in pregnancy, highlighting the key differences in approaches between Asia and Western countries. Presentation topics include: insights into region-specific guidelines; antiviral therapy options; neonatal immunoprophylaxis strategies; and the influence of cultural and health care system factors on care delivery. By comparing practices across regions, the session provides practical knowledge to optimize outcomes for pregnant women with hepatitis B and their newborns in diverse clinical settings.

This disease state education theater will focus on chronic hepatitis B, covering the standard of care, patient care cascade, and clinical management considerations. Expert insights will be shared through engaging case studies and a dynamic panel discussion.<br />
<br />
Industry Supporter:&nbsp;GSK Medical<br />
&nbsp;

Join us for a poster highlight of the top abstracts from the CALD SIG.&nbsp;<br />

Join us for a poster highlight of the top abstracts from the Public Health/Health Care Delivery (PHHD) SIG.&nbsp;<br />
&nbsp;

Join us for a symposium on primary biliary cholangitis (PBC) designed to encourage the exchange of ideas between leaders in the field and attendees.<br />
<br />
<br />
Supported by: Intercept<br />
<br />
Organized by: Medscape Education<br />
<br />
<br />
For more information and to register, visit:&nbsp;<a href="https://events.medscapelive.org/website/88442/">https://events.medscape… />
<br />
Important Note: Continuing education credits for Satellite Symposia are offered by the sponsoring organizations. These sessions are not accredited by AASLD.

Explore hepatocellular carcinoma (HCC) through the lens of living with a chronic disease. From the time of HCC diagnosis, most patients are faced with undergoing lifelong surveillance with regular multiphasic imaging studies and, often, undergoing multiple rounds of treatment including different types of locoregional and systemic therapies. This exacts a substantial toll on quality of life, limits the ability to participate in work and family-related activities, and imposes great symptom, psychological, physical, and financial burdens. Speakers focus on the importance of patients preparing for the long-term trajectory of liver cancer and for physicians to support them in their journey. 

This session will present findings from the Phase 2a PORTOLA trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in autoimmune hepatitis. Attendees will hear insights on the study design and clinical outcomes, followed by expert discussion on the potential role of immunoproteasome inhibition in advancing treatment for this challenging disease.<br />
<br />
Industry Supporter:&nbsp;Kezar Life Sciences, Inc

Join us for a product theater on an FDA-approved treatment option for primary biliary cholangitis (PBC). Gain insights into how this therapy may support improved PBC outcomes for the appropriate patients affected by this chronic liver disease.<br />
<br />
Industry Supporter:&nbsp;Gilead Sciences<br />
<br />
&nbsp;

Learn more about a treatment option for your patients with progressive familial intrahepatic cholestasis (PFIC) or Alagille syndrome (ALGS). Join us as Dr. Sheflin-Findling discusses an overview of PFIC and ALGS and a deep-dive into an approved treatment option for your pediatric, adolescent, and adult patients.<br />
<br />
Industry Supporter:&nbsp;Ipsen Biopharmaceuticals

The following poster categories will be in the Poster Hall:
<ul>
<li>Acute Liver Failure and Artificial Liver Support</li>
<li>Acute on Chronic Liver Failure</li>
<li>Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis</li>
<li>Cell and Molecular Biology</li>
<li>Genomics and Precision Medicine</li>
<li>Gut Liver Axis and Microbiome</li>
<li>Hepatotoxicity</li>
<li>Human Cholestatic and Autoimmune Liver Diseases</li>
<li>Inflammation and Immunobiology</li>
<li>Pediatric Hepatology</li>
<li>Vascular Liver Disease, Hemostasis and Thrombosis</li>
<li>MASLD/MASH -Therapeutics: Approved/available agents</li>
<li>Therapeutics: New Agents - MASLD and MASH</li>
</ul>